Purchase Order 75N93020P01205
- Not listed
- This $8,435.16 firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services' National Institutes of Health, to Genscript USA Inc., a for-profit biotechnology company located in Piscataway, New Jersey. The contract is for antibody production services, with a completion date of June 15, 2018. Genscript specializes in providing a range of biomedical research and public health products and services to...
- This $4,448.22 firm fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for custom protein and DNA synthesis services to support biomedical research and public health initiatives. Genscript specializes in providing a range of molecular biology products and services, including gene...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The $164,700.00 firm fixed-price purchase order is for monoclonal antibodies and plasmids services, with a completion date of June 14, 2026. The contract does not have a set-aside designation. Genscript is a key supplier of...
- This firm fixed-price purchase order contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The $3,943.72 contract is for custom gene synthesis services to support NIAID's biomedical research programs. Genscript, a for-profit organization, has a strong track record of providing specialized molecular biology products and services to...
- This is a $49,653.58 firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the National Institutes of Health (NIH), to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for customized DNA and monoclonal antibody production services, with a completion date of September 5, 2020. Genscript, a for-profit organization, has established itself as a critical vendor for federal...
- The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) awarded a firm fixed-price purchase order contract worth $66,835.54 to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for the custom synthesis of genes and antibodies to support NIAID's biomedical research and public health initiatives. The contract was awarded on a sole-source basis under the authority of FAR 13.106-1 due to Genscript being the...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm-fixed-price purchase order to Genscript USA Inc., a biotechnology company, for gene synthesis services. The $17,000.35 contract has a completion date of December 30, 2020 and was awarded on December 31, 2019. The services provided under this contract supported biomedical research and public health initiatives carried out by the agency. Genscript has...
- The federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to GenScript USA Incorporated, a biotechnology company based in Piscataway, New Jersey. The $35,155.40 firm fixed-price purchase order did not have a set-aside designation. The contract supports GenScript's provision of specialized biological materials and services, including gene synthesis, protein production, and antibody...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm fixed price purchase order to GenScript USA Inc., a for-profit biotechnology company, to provide custom monoclonal antibody production services. The $13,758.30 contract has an October 16, 2019 completion date and was awarded on August 14, 2019. GenScript, based in Piscataway, New Jersey, specializes in gene synthesis, protein production, and other...
- The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $17,709 purchase order to Genscript USA Inc. to provide custom gene synthesis and expression services in support of its research efforts. The firm fixed price contract has a period of performance from September 18, 2023 through December 31, 2023 and will be carried out by Genscript at its facility located in Bethesda, Maryland. No major subcontractors or set aside designations were identified....
The National Institute of Allergy and Infectious Diseases awarded a $16,974.27 firm fixed price purchase order to Genscript USA Inc. for antibody gene synthesis and production services. The contract was awarded on August 26, 2020, with an ultimate completion date of February 6, 2021, and was performed at Genscript's facility in Piscataway, New Jersey. This award did not utilize any set-aside designation and represents a straightforward procurement of specialized molecular biology services critical to NIAID's infectious disease research mission. Genscript USA Inc. is a biotechnology company specializing in advanced molecular biology services, including gene synthesis, protein production, and antibody development. The company maintains an established relationship with federal agencies across the National Institutes of Health, Centers for Disease Control and Prevention, Food and Drug Administration, and Department of Agriculture. This purchase order falls within Genscript's core competencies and reflects the company's ongoing role as a critical vendor supporting federal biomedical research initiatives, particularly in the development of research materials needed for infectious disease studies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00003 | Funding Only Action | ($647) | 7/23/25 | |
| P00001 | Funding Only Action | $35 | 1/8/21 | |
| Not listed | Not listed | $17.6k | 8/26/20 |